Increlex Market Report 2026

Increlex Market Overview

• The Increlex market growth in the historic period has been driven by increasing diagnosis of IGF-1 deficiency, expansion of pediatric endocrinology services • Market expansion is supported by expansion of personalized pediatric growth treatments, rising investments in rare disease therapies • Growth Driver: Impact Of Rising Childhood-Onset Growth Hormone Deficiency (CGHD) On The Increlex Market • North America was the largest region in 2025.

What Is Covered Under Increlex Market?

Increlex is a brand name for mecasermin, a recombinant human insulin-like growth factor-1 (rhIGF-1). It is used to treat growth failure in children with severe primary IGF-1 deficiency or whose bodies do not produce enough insulin-like growth factor-1 (IGF-1), which is critical for normal growth. The main age group of increlex are infants, toddlers, and children aged 5-12 years). Pediatric Patients comprises children diagnosed with severe primary IGF-1 deficiency (SPIGFD), a rare growth disorder where the body lacks sufficient Insulin-such as growth factor 1 (IGF-1) despite adequate growth hormone levels. Increlex (mecasermin) directly addresses this deficiency by mimicking IGF-1, helping improve growth rates and other developmental outcomes. It is distributed through various channels such as hospitals, specialty clinics, online pharmacies, and pharmacies. It has applications in growth hormone deficiency and others.

What Is The Increlex Market Growth Forecast?

The growth in the forecast period can be attributed to expansion of personalized pediatric growth treatments, rising investments in rare disease therapies, increasing adoption of digital growth monitoring tools, growing focus on long-term pediatric outcome optimization, advancement in recombinant protein manufacturing. Major trends in the forecast period include increasing adoption of recombinant growth therapies, rising focus on pediatric endocrine disorders, expansion of precision dosing protocols, improved early diagnosis of growth disorders, enhanced long-term growth monitoring.

What Are The Drivers Of The Increlex Market?

The rise in the prevalence of childhood-onset growth hormone deficiency (CGHD) is expected to propel the growth of the increlex market going forward. Childhood-onset growth hormone deficiency (CGHD) is when the body doesn't produce enough growth hormone during childhood, leading to slower growth and shorter stature. The rise in childhood-onset growth hormone deficiency (CGHD) can be attributed to several factors, particularly advancements in diagnostic methods and an increase in awareness of the condition. The increasing awareness and diagnosis of childhood-onset growth hormone deficiency (CGHD) are driving the demand for Increlex, a synthetic IGF-1 treatment, boosting the market as more children receive adequate therapy. For instance, in November 2023, according to the Council of Health Insurance, a Saudi Arabia-based government office issuing regulatory decisions, childhood-onset growth hormone deficiency is estimated to affect between 1 in 3,500 and 1 in 10,000 children, with a higher prevalence observed in boys. Therefore, the rise in prevalence of childhood-onset growth hormone deficiency (CGHD) is driving the growth of increlex industry. The rise in healthcare expenditure is expected to propel the growth of the increlex market going forward. Healthcare expenditure is the total amount spent on healthcare services, including medical treatments, medications, and hospital care, within a specific period. Healthcare expenditure is rising due to an aging population, increasing healthcare needs, advancements in medical technology, and rising prices for services and medications. The increase in healthcare expenditure contributes to the growth of the increlex market by expanding access to advanced treatments for conditions like childhood-onset growth hormone deficiency (CGHD). For instance, in November 2025, according to Organisation for Economic Co-operation and Development, a France-based intergovernmental international organization, reported that in 2024, average health spending in OECD countries was estimated to stand at nearly USD 6 000 per capita (when adjusted for differences in purchasing power). The United States was the highest spender. Therefore, the rise in healthcare expenditure will drive the growth of the increlex industry.

Key Players In The Global Increlex Market

Major companies operating in the increlex market are Ipsen S.A

What Are Latest Mergers And Acquisitions In The Increlex Market?

In October 2024, Eton Pharmaceuticals Inc., a US-based pharmaceutical company, acquired increlex (mecasermin injection) from Ipsen S.A. for an undisclosed amount. With this acquisition, Ipsen will continue distributing Increlex for six months before Eton takes over commercialization globally. Also, this acquisition will allow Eton to expand its portfolio while ensuring uninterrupted access to Increlex. Ipsen S.A. is a France-based pharma company specializing in drug development, such as Increlex.

What Defines the Increlex Market?

The increlex market consists of sales of increlex injectable solution, increlex pre-filled syringes, and increlex vials. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Increlex Market Report 2026?

The increlex market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the increlex industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.